Immunology and inflammation

News

Lilly bets $2.4bn on Dice’s immune disease platform

Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological dise

News

Sanofi scores in MS with CD40 antibody frexalimab

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L

News

Grünenthal’s non-opioid pain drug gets breakthrough tag

Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Acelyrin raises $540 million in rare biotech IPO

Biotech watchers lamenting a fall-off in public listings for biotech companies will take some heart from Acelyrin’s upsized initial public offering, which ended up at the

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

Lilly bets $2.4bn on Dice’s immune disease platform

Sanofi scores in MS with CD40 antibody frexalimab

Grünenthal’s non-opioid pain drug gets breakthrough tag

XinThera buy builds Gilead’s cancer, inflammation pipeline

Acelyrin raises $540 million in rare biotech IPO

Merck fires up a $10.8bn Prometheus takeover bid

BioNTech sticks with cancer vaccine despite trial miss

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks